Clinical trial
Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs…
NCT00250861 · US Oncology Research, Industry · Terminated
Key facts
| NCT number | NCT00250861 |
|---|---|
| Title | Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma |
| Official title | A Randomized Phase II Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for CD20 Positive Aggressive Non-Hodgkin's Lymphoma Following High Dose Therapy With Autologous PBSC Rescue |
| Lead sponsor | US Oncology Research, Industry |
| Collaborators | Chiron Corporation Industry Fred Hutchinson Cancer Center |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Rituximab, Aldesleukin |
| Enrollment | 110 |
| Start date | Oct 1, 2005 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Nov 8, 2005 |
| Last update posted | Apr 21, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: